Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia

Objective: Schizophrenia is a disease with unknown etiology. There is evidence suggesting that oxidative damage occurs in schizophrenia. Oxidative damage may arouse from imbalance between oxidant and anti-oxidant factors in cellular and tissue environment. Although it may not be the primary cause, i...

Full description

Bibliographic Details
Main Authors: Farnaz Zahei Avval, Niloufar Mahmoudi, Abolfazl Nosrati Tirkani, Lida Jarahi, Daryoush Hamidi Alamdari, Seyed Alireza Sadjadi
Format: Article
Language:English
Published: Tehran University of Medical Sciences 2018-06-01
Series:Iranian Journal of Psychiatry
Subjects:
Online Access:https://ijps.tums.ac.ir/index.php/ijps/article/view/1032
_version_ 1831537457633427456
author Farnaz Zahei Avval
Niloufar Mahmoudi
Abolfazl Nosrati Tirkani
Lida Jarahi
Daryoush Hamidi Alamdari
Seyed Alireza Sadjadi
author_facet Farnaz Zahei Avval
Niloufar Mahmoudi
Abolfazl Nosrati Tirkani
Lida Jarahi
Daryoush Hamidi Alamdari
Seyed Alireza Sadjadi
author_sort Farnaz Zahei Avval
collection DOAJ
description Objective: Schizophrenia is a disease with unknown etiology. There is evidence suggesting that oxidative damage occurs in schizophrenia. Oxidative damage may arouse from imbalance between oxidant and anti-oxidant factors in cellular and tissue environment. Although it may not be the primary cause, it can worsen the disease and may be a reason of poor response to therapy in these patients. The present study aimed at evaluating the pro-oxidant antioxidant balance (PAB) and total antioxidant capacity (TAC) in serum of schizophrenia patients. PAB is an assay to determine the pro-oxidant load and antioxidant capacity in a single measurement. Method: In this cross- sectional study, patients with diagnosis of schizophrenia, who referred to a psychiatry university hospital (Ibn-e-Sina Hospital) affiliated to Mashhad University of Medical Sciences, were enrolled. Patients' demographic characteristics and laboratory data were recorded from patients’ files. Serum PAB and TAC were measured using a special PAB assay and commercial kit, respectively. Data were analyzed using SPSS 16. Results: A total of 84 individuals (42 schizophrenia cases and 42 healthy controls) participated in this study. Controls were age and sex-matched with the patients’ group. The mean TAC in the patient and control groups was 0.49±0.04 and 0.51±0.04 nmol/L, respectively (p = 0.16). PAB was higher in patients’ group than in controls (127.36±36.44 vs. 118.93±52.34 HK), however, this difference was not statistically significant (p = 0.09). The change was correlated with the chronicity of the disease. Conclusion: Pro-oxidant antioxidant balance was elevated in serum of patients with schizophrenia. These data suggested the occurrence of oxidative stress during the progression of the disease. Lower antioxidant capacity might suggest that patients with schizophrenia could be more susceptible to oxidative stress damage.
first_indexed 2024-12-16T23:07:03Z
format Article
id doaj.art-44fe35b0446240928119ddbd1c1e1eac
institution Directory Open Access Journal
issn 1735-4587
2008-2215
language English
last_indexed 2024-12-16T23:07:03Z
publishDate 2018-06-01
publisher Tehran University of Medical Sciences
record_format Article
series Iranian Journal of Psychiatry
spelling doaj.art-44fe35b0446240928119ddbd1c1e1eac2022-12-21T22:12:31ZengTehran University of Medical SciencesIranian Journal of Psychiatry1735-45872008-22152018-06-01133638Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with SchizophreniaFarnaz Zahei Avval0Niloufar Mahmoudi1Abolfazl Nosrati Tirkani2Lida Jarahi3Daryoush Hamidi Alamdari4Seyed Alireza Sadjadi5Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.and Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Psychiatry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Community Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Clinical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.and Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.Department of Community Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.and Psychiatry and Behavioral Sciences Research Center, Ibn-e-Sina Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.Objective: Schizophrenia is a disease with unknown etiology. There is evidence suggesting that oxidative damage occurs in schizophrenia. Oxidative damage may arouse from imbalance between oxidant and anti-oxidant factors in cellular and tissue environment. Although it may not be the primary cause, it can worsen the disease and may be a reason of poor response to therapy in these patients. The present study aimed at evaluating the pro-oxidant antioxidant balance (PAB) and total antioxidant capacity (TAC) in serum of schizophrenia patients. PAB is an assay to determine the pro-oxidant load and antioxidant capacity in a single measurement. Method: In this cross- sectional study, patients with diagnosis of schizophrenia, who referred to a psychiatry university hospital (Ibn-e-Sina Hospital) affiliated to Mashhad University of Medical Sciences, were enrolled. Patients' demographic characteristics and laboratory data were recorded from patients’ files. Serum PAB and TAC were measured using a special PAB assay and commercial kit, respectively. Data were analyzed using SPSS 16. Results: A total of 84 individuals (42 schizophrenia cases and 42 healthy controls) participated in this study. Controls were age and sex-matched with the patients’ group. The mean TAC in the patient and control groups was 0.49±0.04 and 0.51±0.04 nmol/L, respectively (p = 0.16). PAB was higher in patients’ group than in controls (127.36±36.44 vs. 118.93±52.34 HK), however, this difference was not statistically significant (p = 0.09). The change was correlated with the chronicity of the disease. Conclusion: Pro-oxidant antioxidant balance was elevated in serum of patients with schizophrenia. These data suggested the occurrence of oxidative stress during the progression of the disease. Lower antioxidant capacity might suggest that patients with schizophrenia could be more susceptible to oxidative stress damage.https://ijps.tums.ac.ir/index.php/ijps/article/view/1032Pro-Oxidant Antioxidant BalanceReactive Oxygen SpeciesSchizophreniaTotal Antioxidant Capacity
spellingShingle Farnaz Zahei Avval
Niloufar Mahmoudi
Abolfazl Nosrati Tirkani
Lida Jarahi
Daryoush Hamidi Alamdari
Seyed Alireza Sadjadi
Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia
Iranian Journal of Psychiatry
Pro-Oxidant Antioxidant Balance
Reactive Oxygen Species
Schizophrenia
Total Antioxidant Capacity
title Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia
title_full Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia
title_fullStr Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia
title_full_unstemmed Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia
title_short Determining Pro-Oxidant Antioxidant Balance (PAB) and Total Antioxidant Capacity (TAC) in Patients with Schizophrenia
title_sort determining pro oxidant antioxidant balance pab and total antioxidant capacity tac in patients with schizophrenia
topic Pro-Oxidant Antioxidant Balance
Reactive Oxygen Species
Schizophrenia
Total Antioxidant Capacity
url https://ijps.tums.ac.ir/index.php/ijps/article/view/1032
work_keys_str_mv AT farnazzaheiavval determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia
AT niloufarmahmoudi determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia
AT abolfazlnosratitirkani determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia
AT lidajarahi determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia
AT daryoushhamidialamdari determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia
AT seyedalirezasadjadi determiningprooxidantantioxidantbalancepabandtotalantioxidantcapacitytacinpatientswithschizophrenia